<DOC>
	<DOC>NCT00931021</DOC>
	<brief_summary>This is a pilot research study examining the use of varenicline (Chantix) and the nicotine patch. The study is designed to find out whether one of these medications is more effective for smoking cessation with head and neck cancer patients. The study has three parts: 1) two intake sessions; 2) an 8-week treatment phase, and 3) a 3-month follow-up.</brief_summary>
	<brief_title>Smoking Cessation Treatment for Head and Neck Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>age 18 or older smoking 10 or more cigarettes per day diagnosed with and completed an initial course of treatment for any type of head and neck cancer life expectancy of 12 months or more history of allergic reactions to adhesives unstable psychiatric/medical conditions such as suicidal ideation, acute psychosis, severe alcohol dependence, or dementia females of childbearing potential who are pregnant, nursing, or not practicing effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>